Clinical trial · Interventional
Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regimen For Patients With Refractory Hematologic Malignancies
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Patients with refractory hematologic malignancies including those who develop recurrent disease after allogeneic hematopoietic stem cell transplantation (HSCT) have a dismal prognosis. Historically, both regimen-related mortality and disease recurrence have been significant causes of treatment failure in this heavily pre-treated patient population. The investigators institution has utilized mismatched family member donors for these patients for several reasons: (1) Only 30% of patients have matched related donors available; (2) transplantation can be performed more rapidly since the time to unrelated donor trans-plantation averages 3 to 4 months; (3) the alloimmune reactivity of natural killer (NK) cells following haploidentical HSCT has been shown to reduce relapse rates in certain patient groups; and, (4) no other curative treatment options are available. In the present trial, the investigators propose a novel conditioning regimen using clofarabine in an effort to enhance cytotoxicity while simultaneously reducing regimen related toxicity. In this phase I trial, the goal is to determine the maximum tolerated dose (MTD) of clofarabine when used in combination with melphalan and thiotepa pre-transplant.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hematologic Malignancies | Hematopoietic and Lymphoid Cell Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (8)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Clofarabine | Drug | Clofarabine | ALIAS |
| G-CSF | Other | — | UNRESOLVED |
| Melphalan | Drug | Melphalan | ALIAS |
| Mycophenolate mofetil | Drug | — | UNRESOLVED |
| OKT3 | Other | — | UNRESOLVED |
| Rituximab | Drug | Rituximab | ALIAS |
| Stem Cell Transplantation, Hematopoietic | Procedure | — | UNRESOLVED |
| Thiotepa | Drug | Thiotepa | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 1
- interventionNames
- Drug: Clofarabine
- Procedure: Stem Cell Transplantation, Hematopoietic
- Other: OKT3
- Drug: Thiotepa
- Drug: Melphalan
- Drug: Mycophenolate mofetil
- Drug: Rituximab
- Other: G-CSF
Primary outcomes (1)
- measure
- To determine the MTD and DLT of clofarabine in combination with thiotepa and melphalan as a conditioning regimen for a haploidentical HSCT with an engineered graft depleted of CD3+ cells obtained by negative selection with OKT3 on the CliniMACS system.
- timeFrame
- 30 days
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 21 Years
Show eligibility criteria text
Inclusion Criteria: * Age less than or equal to 21 years old; may be greater than 21 years old if a previously treated St. Jude patient and within 3 years of completion of most recent prior disease specific therapy. * One of the following refractory hematologic malignancies (chemoresistant relapse or primary induction failure) or diagnoses: * ALL * AML (\>25% blasts in the bone marrow) * secondary AML/MDS * CML in accelerated phase or blast crisis * juvenile myelomonocytic leukemia (JMML) * myelodysplastic syndrome (MDS) * Hodgkin or non-Hodgkin lymphoma (NHL) with residual or recurrent disease following autologous HSCT, who are unable to undergo autologous HSCT due to chemo-resistant disease or inability to have an acceptable quantity of tumor-free stem cells collected (\> 1 x 108 TNC/kg marrow or \> 1 x 106 CD34+/kg PBS * patients with a hematologic malignancy who have undergone prior allogeneic HSCT or who have a co-morbid condition that in the medical opinion of medical faculty (Division of Bone Marrow Transplantation and Cellular Therapy) makes standard myeloablation prohibitive * Does not have any other active malignancy other than the one for which this transplant is indicated * Cardiac shortening fraction greater than or equal to 25% * For pediatric patients, creatinine clearance greater than or equal to 90 ml/min/1.73 m2 according to the Schwartz formula for estimated GFR (ml/min/1.73m2) = k\*height (cm)/serum creatinine (mg/dL). k is a proportionality constant that varies with age and is a function of urinary creatinine clearance per unit of body size; 0.45 up to 12 months of age; 0.55 children and adolescent girls; and 0.70 for adolescent boys * For adolescent or adult patients, serum creatinine 1.0 mg/dL; if serum creatinine 1.0 mg/dL, then the estimated glomerular filtration rate (GFR) must be 60 mL/min/1.73 m2 as calculated by the Modification of Diet in Renal Disease equation where predicted GFR (ml/min/1.73 m2) = 186 x (serum creatinine)-1.154 x (age in years)-0.023 x (0.742 if patient is female) x (1.212 if patient is black) * Forced vital capacity (FVC) greater than or equal to 40% of predicted value or pulse oximetry greater than or equal to 92% on room air. * Karnofsky or Lansky (age-dependent) performance score of greater than or equal to 50 (See APPENDIX A) * Does not have active acute or active chronic GVHD defined as requiring medical therapy. * Does not have active acute bronchiolitis obliterans (BO) or bronchiolitis obliterans organizing pneumonia (BOOP). * Has a suitable HLA partially matched family member donor available for stem cell donation * Bilirubin less than or equal to 1.5 times the upper limit of normal for age. * Alanine aminotransferase (ALT) less than or equal to 1.5 times the upper limit of normal for age. * Aspartate aminotransferase (AST) less than or equal to 1.5 times the upper limit of normal for age. * Not pregnant (confirmed by negative serum or urine pregnancy test within 14 days prior to enrollment). * Not lactating Inclusion criteria (stem cell donor): * Partially HLA-matched family member. * At least 18 years of age. * HIV negative * Not pregnant (confirmed by negative serum or urine pregnancy test within 14 days prior to enrollment). * Not lactating
References
Publications (0)
Data not yet available